Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MNK - Mallinckrodt Plc - New


Previous close
0.3402
0   0%

Share volume: 543,145
Last Updated: Fri 25 Aug 2023 06:00:00 AM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$0.34
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
14%
Profitability 8%
Dept financing 20%
Liquidity 14%
Performance 20%
Company vs Stock growth
vs
Performance
5 Days
-39.20%
1 Month
-68.50%
3 Months
-88.66%
6 Months
-96.42%
1 Year
-97.86%
2 Year
-97.86%
Key data
Stock price
$0.34
P/E Ratio 
-0.00
DAY RANGE
$0.30 - $0.41
EPS 
-$25.50
52 WEEK RANGE
$0.30 - $18.10
52 WEEK CHANGE
-$0.98
MARKET CAP 
4.521 M
YIELD 
N/A
SHARES OUTSTANDING 
13.289 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$701,646
AVERAGE 30 VOLUME 
$3,566,568
Company detail
CEO: Mark Trudeau
Region: US
Website: http://www.mallinckrodt.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit

Recent news